TEL1.F SIHUAN PHARMACE
- Market cap
- EUR 807M
- P/E
- -
- P/B
- 1.01x
- ROE
- 3.1%
- Dividend yield
- 2.66%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is TEL1.F undervalued?
Graham numberThe Graham number of SIHUAN PHARMACE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SIHUAN PHARMACE fundamental analysis
No fundamental analysis for SIHUAN PHARMACE yet.
SIHUAN PHARMACE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SIHUAN PHARMACE
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculptu…
Full company profileSIHUAN PHARMACE financial statements
SIHUAN PHARMACE annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.04B | 2.18B | 1.86B | 1.90B | 2.62B |
| Gross Profit | 2.43B | 1.49B | 1.30B | 1.24B | 1.80B |
| Operating Income | 648M | -554M | -191M | -462M | 375M |
| EBITDA | - | -1.54B | 334M | 105M | 844M |
| Net Income | 417M | -1.91B | -54.0M | -217M | 180M |
| EPS | 0.04 | -0.21 | -0.01 | -0.02 | 0.02 |
| Balance Sheet | |||||
| Total Assets | 14.5B | 12.1B | 11.5B | 10.5B | 11.6B |
| Total Liabilities | 5.35B | 6.50B | 6.40B | 5.58B | 4.73B |
| Shareholders' Equity | 8.28B | 4.74B | 4.43B | 4.37B | 5.85B |
| Cash & Short-term Investments | 5.68B | 4.01B | 3.78B | 3.52B | 3.56B |
| Cash Flow | |||||
| Operating Cash Flow | 665M | 46.5M | 199M | 276M | -23.6M |
| Capital Expenditure | 767M | 594M | 295M | 186M | 195M |
| Free Cash Flow | -102M | -547M | -95.9M | 89.8M | -218M |
| Ratios | |||||
| ROE | 5.0% | -40.4% | -1.2% | -5.0% | 3.1% |
| ROA | 2.9% | -15.8% | -0.5% | -2.1% | 1.5% |
| Net Profit Margin | 13.7% | -87.8% | -2.9% | -11.4% | 6.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SIHUAN PHARMACE dividends
- Dividend yield
- 2.66%
- Forward dividend
- -
- Payout ratio
- 50.6%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 90.9M | 0.01 | 50.6% |
| 2024 | CNY 177M | 0.02 | - |
| 2023 | CNY 299M | 0.03 | - |
| 2022 | CNY 1.32B | 0.14 | - |
| 2021 | CNY 123M | 0.01 | 29.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 5, 2014.
Who owns SIHUAN PHARMACE
- Insiders 56.31%
- Institutions 7.76%
- Public & others 35.93%
- Shares outstanding 9.12B
- Free float 3.66B
SIHUAN PHARMACE company profile
- Company name
- SIHUAN PHARMACE
- Ticker
- TEL1.F
- ISIN
- BMG8162K1137
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,712
- Fiscal year end
- December
- Address
- Office Tower, Convention Plaza, Wan Chai, Hong Kong
- Phone
- 852 3628 3911
- Website
- sihuanpharm.com
About SIHUAN PHARMACE
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions. It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
SIHUAN PHARMACE management
7- Dr. Fengsheng CheCo-Founder & Executive Chairman · born 1962
- Dr. Weicheng Guo Ph.D.Deputy Chairman & CEO · born 1964
- Dr. Jionglong Zhang Ph.D.Executive Director · born 1962
- Ms. Yanling ChenJoint Company Secretary & Executive Director · born 1978
- Ms. Xiaomi SongChief Financial Officer · born 1967
- Mr. Kin Wai LiJoint Company Secretary · born 1989
- Mr. Xianhui MengDeputy General Manager · born 1964